Tofacitinib has received expanded approval to treat adults with moderate to severe ulcerative colitis. The drug was approved in 2012 to treat rheumatoid arthritis and in 2017 for patients with psoriatic arthritis.
As a Janus kinase inhibitor, tofacitinib works intracellularly to disrupt activities in signaling pathways involved in inflammation. Although other FDA-approved medications for the chronic treatment of ulcerative colitis are given as an intravenous infusion or subcutaneous injection, tofacitinib is the first oral treatment approved for this indication.
Voelker R. New Relief for Ulcerative Colitis. JAMA. 2018;320(1):23. doi:10.1001/jama.2018.8554
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: